TNFSF10 and neoplasm: The potential clinical relevance was underlined by data showing that TRAIL and Bortezomib cooperated to trigger apoptosis in primary cultured glioblastoma cells and in patient-derived glioblastoma stem cells and to suppress tumor growth in an in vivo glioblastoma model37.